Risk assessment and pathological reporting of gastrointestinal stromal tumour

Diagnostic Histopathology

Volumn 19, Issue 6, 2013, Pages 191-197

  Agaimy, Abbas ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Adjuvant treatment; Gastrointestinal stromal tumour; GIST; KIT mutation; Risk assessment; Rupture; Serosal penetration; Tyrosine kinase inhibitor

Indexed keywords

ANTINEOPLASTIC AGENT; B RAF KINASE; CYCLIN DEPENDENT KINASE INHIBITOR 2A; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PROTEIN P16; PROTEIN TYROSINE KINASE INHIBITOR; STEM CELL FACTOR RECEPTOR;

ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER INFILTRATION; CANCER LOCALIZATION; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RISK; CANCER SIZE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CARCINOMATOSIS; CELL HETEROGENEITY; CHROMOSOME ABERRATION; DISEASE FREE SURVIVAL; FOLLOW UP; GASTROINTESTINAL STROMAL TUMOR; GOLD STANDARD; HISTOLOGY; HUMAN; LIVER METASTASIS; MITOSIS RATE; MOLECULARLY TARGETED THERAPY; MULTIMODALITY CANCER THERAPY; PATHOGENESIS; PATIENT CARE; PRIMARY TUMOR; PROTEIN EXPRESSION; REVIEW; RISK ASSESSMENT; TUMOR INVASION; TUMOR SUPPRESSOR GENE;

EID: 84878667279     PISSN: 17562317     EISSN: 18767621     Source Type: Journal    
DOI: 10.1016/j.mpdhp.2013.03.001     Document Type: Review

References (28)

1. Miettinen M., Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol 2006, 23:70-83.
2. Zhang L., Smyrk T.C., Young W.F., et al. Gastric stromal tumors in Carney triad are different clinically, pathologically, and behaviorally from sporadic gastric gastrointestinal stromal tumors: findings in 104 cases. Am J Surg Pathol 2010, 34:53-64.
3. Rutkowski P., Nowecki Z.I., Michej W., et al. Risk criteria and prognostic factors for predicting recurrences after resection of primary gastrointestinal stromal tumor. Ann Surg Oncol 2007, 14:2018-2027.
4. Joensuu H. Risk stratification of patients diagnosed with gastrointestinal stromal tumor. Hum Pathol 2008, 39:1411-1419.
5. Agaimy A., Dirnhofer S., Wünsch P.H., Terracciano L.M., Tornillo L., Bihl M.P. Multiple sporadic gastrointestinal stromal tumors (GISTs) of the proximal stomach are caused by different somatic KIT mutations suggesting a field effect. Am J Surg Pathol 2008, 32:1553-1559.
6. Agaimy A., Märkl B., Arnholdt H., et al. Multiple sporadic gastrointestinal stromal tumours arising at different gastrointestinal sites: pattern of involvement of the muscularis propria as a clue to independent primary GISTs. Virchows Arch 2009, 455:101-108.
7. Lasota J., Miettinen M. Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumours. Histopathology 2008, 53:245-266.
8. Blay J.Y., von Mehren M., Blackstein M.E. Perspective on updated treatment guidelines for patients with gastrointestinal stromal tumors. Cancer 2010, 116:5126-5137. 10.1002/cncr.25267.
9. Gastrointestinal stromal tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012, 23(suppl 7):vii49-55. ESMO/European Sarcoma Network Working Group.
10. Miettinen M., Furlong M., Sarlomo-Rikala M., Burke A., Sobin L.H., Lasota J. Gastrointestinal stromal tumors, intramural leiomyomas, and leiomyosarcomas in the rectum and anus: a clinicopathologic, immunohistochemical, and molecular genetic study of 144 cases. Am J Surg Pathol 2001, 25:1121-1133.
11. Agaimy A. Gastrointestinal stromal tumors (GIST) from risk stratification systems to the new TNM proposal: more questions than answers? A review emphasizing the need for a standardized GIST reporting. Int J Clin Exp Pathol 2010, 3:461-471.
12. Fletcher C.D., Berman J.J., Corless C., et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol 2002, 33:459-465.
13. TNM classification of malignant tumours 2010, International Union Against Cancer (UICC), Wiley, New York. 7th ed. L.H. Sobin, C. Wittekind (Eds.).
14. Rubin B.P., Blanke C.D., Demetri G.D., et al. Protocol for the examination of specimens from patients with gastrointestinal stromal tumor. Arch Pathol Lab Med 2010, 134:165-170.
15. Hohenberger P., Ronellenfitsch U., Oladeji O., et al. Pattern of recurrence in patients with ruptured primary gastrointestinal stromal tumour. Br J Surg 2010, 97:1854-1859.
16. Vallböhmer D., Marcus H.E., Baldus S.E., et al. Serosal penetration is an important prognostic factor for gastrointestinal stromal tumors. Oncol Rep 2008, 20:779-783.
17. Agaimy A., Vassos N., Wunsch P.H., Hohenberger W., Hartmann A., Croner R.S. Impact of serosal involvement/extramural growth on the risk of synchronous and metachronous peritoneal spread in gastrointestinal stromal tumors: proposal for a macroscopic classification of GIST. Int J Clin Exp Pathol 2012, 5:12-22.
18. Miettinen M., Lasota J., Sobin L.H. Gastrointestinal stromal tumors of the stomach in children and young adults: a clinicopathologic, immunohistochemical, and molecular genetic study of 44 cases with long-term follow-up and review of the literature. Am J Surg Pathol 2005, 29:1373-1381.
19. Agaimy A., Haller F., Gunawan B., Wünsch P.H., Füzesi L. Distinct biphasic histomorphological pattern in gastrointestinal stromal tumours (GISTs) with common primary mutations but divergent molecular cytogenetic progression. Histopathology 2009, 54:295-302.
20. Haller F., Cortis J., Helfrich J., et al. Epithelioid/mixed phenotype in gastrointestinal stromal tumors with KIT mutation from the stomach is associated with accelerated passage of late phases of the cell cycle and shorter disease-free survival. Mod Pathol 2011, 24:248-255.
21. Haller F., Agaimy A., Cameron S., et al. Expression of p16INK4A in gastrointestinal stromal tumours (GISTs): two different forms exist that independently correlate with poor prognosis. Histopathology 2010, 56:305-318.
22. Agaimy A., Wang L.M., Eck M., Haller F., Chetty R. Loss of DOG-1 expression associated with shift from spindled to epithelioid morphology in gastric gastrointestinal stromal tumors with KIT and platelet-derived growth factor receptor ? mutations. Ann Diagn Pathol 2013, 17:187-191. S1092-9134(12)00146-3. 10.1016/j.anndiagpath.2012.10.005.
23. Wardelmann E., Losen I., Hans V., et al. Deletion of Trp-557 and Lys-558 in the juxtamembrane domain of the c-kit protooncogene is associated with metastatic behavior of gastrointestinal stromal tumors. Int J Cancer 2003, 106:887-895.
24. Everett M., Gutman H. Surgical management of gastrointestinal stromal tumors: analysis of outcome with respect to surgical margins and technique. JSurg Oncol 2008, 98:588-593.
25. Takahashi T., Nakajima K., Nishitani A., et al. An enhanced risk-group stratification system for more practical prognostication of clinically malignant gastrointestinal stromal tumors. Int J Clin Oncol 2007, 12:369-374.
26. Gold J.S., Gönen M., Gutiérrez A., et al. Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis. Lancet Oncol 2009, 10:1045-1052.
27. Rossi S., Miceli R., Messerini L., et al. Natural history of imatinib-naive GISTs: a retrospective analysis of 929 cases with long-term follow-up and development of a survival nomogram based on mitotic index and size as continuous variables. Am J Surg Pathol 2011, 35:1646-1656.
28. Joensuu H., Vehtari A., Riihimäki J., et al. Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts. Lancet Oncol 2012, 13:265-274.